Author

Y. Landesman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Aboukameel· 2 shared A. S. Azmi· 2 shared H. Y. Khan· 2 shared M. H. Uddin· 2 shared M. N. Al-Hallak· 2 shared R. Beydoun· 2 shared S. Bannoura· 2 shared S. Kim· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Aboukameel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells by XPO1 inhibitors

C. Jing, N. Prutsch, S. He, M. W. Zimmerman, Y. Landesman, A. T. W. Look

This study identifies XPO1 inhibitors as selective killers of TET2-mutant HSPCs and AML cells through apoptosis, without DNA damage.

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer model

M. H. Uddin, A. Aboukameel, Y. Li, H. Y. Khan, R. E. Sexton, S. Bannoura, G. Dyson, M. N. Al-Hallak, Y. Mzannar, A. Mohamed, Y. Landesman, S. Kim, R. Beydoun, R. M. Mohammad, A. F. Shields, A. S. Azmi

This study investigates the synergy between XPO1 inhibitor selinexor and gemcitabine-nab-paclitaxel in pancreatic cancer using cellular and mouse models, showing improved survival and molecular changes.

bioRxiv · Mar 8, 2022 · PreprintCancer Biology

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers

H. Y. Khan, M. Nagasaka, Y. Li, A. Aboukameel, M. H. Uddin, R. Sexton, S. Bannoura, Y. Mzannar, M. N. Al-Hallak, S. Kim, R. Beydoun, Y. Landesman, H. Mamdani, D. Uprety, P. A. Philip, , A. S. Azmi

This paper shows that combining XPO1 inhibitor selinexor with KRAS G12C inhibitors enhances antitumor effects in preclinical models of KRAS G12C mutant cancers.

bioRxiv · Jan 26, 2022Cancer Biology

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

G. Pianigiani, A. Gagliardi, F. Mezzasoma, F. Rocchio, V. Tini, B. Bigerna, P. Sportoletti, S. Caruso, A. Marra, G. Spinozzi, S. Shacham, Y. Landesman, C. Quintarelli, F. Locatelli, M. P. Martelli, , L. Brunetti

This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.

bioRxiv · Dec 11, 2021 · PreprintCancer Biology